|We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.|
Current Price .13
52 wk High .95
NNLX DD Has patent and plant for cheapest HYDROGEN production system in the world: Initial Target $1.00... Float approx. 19 million, O/S 40 million shares, Market Cap at .11/share a paltry $4.4 million with top class Execs running the company...
For instance, David F. Rivers, a director of NanoLogix, CEO of Patriot Lift Company spent more than 30 years with Pfizer's Schick & Wilkinson Sword business unit and General Motors' Fisher Body Division in Senior Research, Development and Engineering operations...
Move to Bulletin Board: Applied for in January 2006 and should occur within 3 to 4 months of application date...
Product: Gas containing 50% Hydrogen WHITHOUT the need to extract Methane, using NO electrical power, except for waste heat and consumming bothersome wastes in the process is a Huge improvement on what currently exists...
First technology user: Welch is a prestigious company with $600 million in sales: for it to get involved with NNLX, its Technology has to be the best of breed and the same goes for its management: it's exceptionally rare to discover such GEM @6 cents/share...
NEWS March 13: NanoLogix Announces Completion of Welch's Hydrogen Bioreactor Facility and Commencement of Hydrogen Production:
NanoLogix, Inc. announced today that the Company has completed the construction of its first commercial hydrogen bioreactor facility at a Welch's Food plant in North East, Pennsylvania. The company also announced that the facility will begin hydrogen generation from Welch's waste organic matter on or about the first of April 2006.
Patents and Applications:
Brief and broad overview -- "The convergence of science, medicine and technology is on the cusp of yielding extraordinary breakthroughs as patents that were once designed to identify bacteria have widespread applications across multiple markets. NanoLogix's portfolio of 31 patents have yielded a method vital to the development of nanotechnology products, a method for low cost hydrogen production, FDA registered products in the medical device industry, a genomic cancer therapy and methods for cleaning up toxic environments using bioremediation. According to Lux Research,
Sales of products that incorporate nanotechnology are expected to explode over the next five years, from $12.98 billion in 2004 to an estimated $507.74 billion in 2010, according to Lux Research. NanoLogix's patents have nanotechnology applications in hydrogen gas production, medical drugs/devices, bio-defense sensors and bioremediation. Nanotechnology applications include biochips embedded in small transportable devices for rapid bacteria identification of disease causing pathogens, and Bio Micro Electro Mechanical Systems for rapid environmental microbial monitoring with bio-defense implications".
Highlights of the agreement with Nutra Pharma, which tried to buy-out NNLX for its very valuable Patents:
NanoLogix will reassign to Nutra Pharma 11 key patents protecting the diagnostics test kit technology in exchange for Nutra Pharma's entire holding of NanoLogix stock (over 4.5 million shares). -- (that is over 4,500,000 shares returned to NanoLogix treasury)!
NanoLogix will license to Nutra Pharma the remaining 18 patents that protect the diagnostics test kit technology in exchange for a 6% royalty on the GROSS sales of the products based on the licensed technology. IMO -- (that is 6% of an estimated $300 million market equaling a potential $18,000,000 in annual licensing revenue to NanoLogix on this segment of the agreement alone)!
Nutra Pharma will issue 1 million options of Nutra Pharma restricted common stock to NanoLogix at .20 per share. IMO -- (this may, and most likely will be a huge, and I mean enormous asset to NanoLogiox balance sheet and overall enterprise value)
Nutra Pharma will allow NanoLogix to continue their use of these patents for development of their hydrogen technology and other technologies unrelated to medical diagnostic test kits. [and if that weren't enough, the cherry on top -- full use (with the exception of test kits) of all reassigned patents. Talk about having your cake and eating it too.]
It has been my experience that stocks with what appears to be a sound business plan, an impressive patent portfolio, relatively low O/S, licensing and royalties going forward, in a sector that is (for lack of a better word) ... sexy -- breaks out to fully reporting status; typically run from pennies to dollars...
Conclusions as to the potential of NNVX:
This powerful and efficient technology can be licensed all over the world in addition to the huge potential in the US and in my view, these Patents are worth several hundred Millions Dollars, yet, NNLX market Cap is still only $4.5 million...
This is just the first day of a new era for NNLX stock price with $1.00 as initial target and $5.00 to $10.00 within 18 months. In the same vein, EPG I reco'ed at $5.10 had a high of $10.70 and produces/sells Methane obtained from cow dung: it was once @$1.20...
At $1.00 - which should occur in less than a month, judging by the way it climbed from .06 to .90 in November 2005 on the Weekly Chart
Source: "From the lion"
|© 2022 Knight Sac Media. Data provided by IEX, Alpha Vantage, Coinbase, Binance, Fintel and CityFALCON News|